Aptevo reports preclinical data for APVO451, APVO452 and APVO711 at SITC 2026
Aptevo said APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation in preclinical studies under immunosuppressive conditions. It also said APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings. The data were presented at the SITC 2026 Annual Meeting on November 7, 2026; no financial results or guidance were disclosed.
Key takeaways
Preclinical activity: APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation under immunosuppressive conditions.
APVO451 and APVO452 design: Both molecules combine CD40 activation with T-cell engagement.
APVO711 mechanism: Preclinical findings showed CD40 activation combined with PD-L1 checkpoint blockade.
Development timeline: APVO451 and the first Niowave radiopharmaceutical program are expected to advance into IND-enabling studies in 2027.
Niowave collaboration: Aptevo is developing up to three radiopharmaceutical oncology programs, with the first expected to target nectin-4.
Evidence scope: The reported findings were preclinical and did not establish clinical efficacy or safety in patients.
Pipeline: Aptevo reported eight pipeline candidates created using its ADAPTIR and ADAPTIR-FLEX platforms.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow APVO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.